A large Nordic study using nationwide data from Sweden, Denmark, and Norway (2013–2021) compared over 120,000 GLP-1 RA users to 185,000 SGLT-2 inhibitor users, and no significant difference in bowel obstruction risk was found. The gene discussed is SLC5A2; the disease is intestinal obstruction.